These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 12629355)

  • 1. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
    Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
    J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
    Yoshida S; Nakagomi K; Goto S; Futatsubashi M; Torizuka T
    Urol Int; 2005; 74(3):214-20. PubMed ID: 15812206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
    Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
    BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
    Giovacchini G; Picchio M; Briganti A; Cozzarini C; Scattoni V; Salonia A; Landoni C; Gianolli L; Di Muzio N; Rigatti P; Montorsi F; Messa C
    J Urol; 2010 Sep; 184(3):938-43. PubMed ID: 20643445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.
    de Jong IJ; Pruim J; Elsinga PH; Vaalburg W; Mensink HJ
    Eur Urol; 2003 Jul; 44(1):32-8; discussion 38-9. PubMed ID: 12814672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
    Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
    Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
    Nanni C; Schiavina R; Brunocilla E; Borghesi M; Ambrosini V; Zanoni L; Gentile G; Vagnoni V; Romagnoli D; Martorana G; Fanti S
    Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
    Rinnab L; Mottaghy FM; Blumstein NM; Reske SN; Hautmann RE; Hohl K; Möller P; Wiegel T; Kuefer R; Gschwend JE
    BJU Int; 2007 Oct; 100(4):786-93. PubMed ID: 17822459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
    Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
    World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.
    Pelosi E; Arena V; Skanjeti A; Pirro V; Douroukas A; Pupi A; Mancini M
    Radiol Med; 2008 Sep; 113(6):895-904. PubMed ID: 18414809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
    Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
    Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.